Non-hormonal steroid modulators of NF-KB for treatment of disease
申请人:ReveraGen BioPharma, Inc.
公开号:EP2805720B1
公开(公告)日:2019-08-07
ANTAGONISTS OF CB1 RECEPTOR
申请人:INSERM (Institut National de la Sante et de la Recherche Medicale)
公开号:US20220153776A1
公开(公告)日:2022-05-19
The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.